Sanofi India Limited Announces 70th AGM on April 29, 2026, with ₹48 Dividend
Sanofi India Limited will hold its 70th AGM on April 29, 2026, via VC/OAVM. A final dividend of ₹48 per share will be paid on or before May 28, 2026. The record date for the dividend is April 22, 2026. The company is also facilitating KYC updates and a special window for physical security dematerialization.
The announcement concerns the AGM and dividend, which are important for shareholders, and includes details about KYC and a special SEBI window, impacting a segment of shareholders.
The announcement is a routine update regarding the upcoming AGM, dividend details, and regulatory compliance, with no significant positive or negative financial or operational news.
Sanofi India Limited has announced the dispatch of letters to its members containing the Notice of the 70th Annual General Meeting (AGM) and the Integrated Annual Report for the financial year ended December 31, 2025. The AGM is scheduled to be held on Wednesday, April 29, 2026, at 3:30 PM IST through Video Conferencing / Other Audio Visual Means.
For members whose email addresses are not registered, the company is providing a weblink and QR code to access the AGM notice and annual report. The report and notice are also available on the websites of BSE, NSE, and NSDL. Key details for the 70th AGM include a final dividend of ₹48 per share, with the record date and cut-off date for e-voting and AGM participation set for Wednesday, April 22, 2026. Remote e-voting will be open from Saturday, April 25, 2026, 9:00 am IST, to Tuesday, April 28, 2026, 5:00 pm IST. The dividend payment date is on or before May 28, 2026.
The company also provided information on registering KYC details, including bank account details, for both physical and dematerialized shareholders. Additionally, Sanofi India Limited highlighted a special window opened by SEBI from February 5, 2026, to February 4, 2027, for the transfer and dematerialization of physical securities sold or purchased before April 1, 2019.
What to do with a filing like this
Sanofi India Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sanofi India Limited. Read the original for the full detail.